Evaluation of Vancomycin Dose Needed to Achieve 24-Hour Area Under the Concentration-Time Curve to Minimum Inhibitory Concentration Ratio Greater Than or Equal to 400 Using Pharmacometric Approaches in Pediatric Intensive Care Patients

被引:0
作者
Jung, Dawoon [1 ]
Kishk, Omayma A. [2 ,3 ]
Bhutta, Adnan T. [4 ,5 ]
Cummings, Ginny E. [6 ]
El Sahly, Hana M. [7 ]
Virk, Manpreet K. [8 ]
Moffett, Brady S. [9 ,10 ,11 ]
Morris Daniel, Jennifer L. [9 ,10 ,12 ]
Watanabe, Amy [13 ]
Fishbane, Nicholas [13 ]
Kotloff, Karen L. [6 ]
Gu, Kenan [14 ]
Ghazaryan, Varduhi [14 ]
Gobburu, Jogarao V. S. [1 ]
Akcan-Arikan, Ayse [15 ,16 ]
Campbell, James D. [6 ]
机构
[1] Univ Maryland, Sch Pharm, Ctr Translat Med, Baltimore, MD USA
[2] Univ Maryland, Med Ctr, Dept Pharm, Baltimore, MD USA
[3] US FDA, US Food & Drug Adm, Silver Spring, MD 20903 USA
[4] Univ Maryland, Sch Med, Dept Pediat, Div Pediat Crit Care Med, Baltimore, MD USA
[5] Indiana Univ Sch Med, Pediat Crit Care Med, Riley Childrens Hlth, Indianapolis, IN USA
[6] Univ Maryland, Ctr Vaccine Dev & Global Hlth, Sch Med, Dept Pediat, Baltimore, MD 21201 USA
[7] Baylor Coll Med, Dept Mol Virol & Microbiol & Med, Houston, TX USA
[8] Baylor Coll Med, Texas Childrens Hosp, Dept Pediat, Sect Crit Care Med, Houston, TX USA
[9] Texas Childrens Hosp, Dept Pharm, Houston, TX USA
[10] Baylor Coll Med, Dept Pediat, Houston, TX USA
[11] Novartis, Med Sci Liaison, Houston, TX USA
[12] Imagine Pediat, Houston, TX USA
[13] Emmes Co LLC, Rockville, MD USA
[14] NIAID, Div Microbiol & Infect Dis, Bethesda, MD USA
[15] Baylor Coll Med, Texas Childrens Hosp, Dept Pediat, Div Crit Care Med, Houston, TX USA
[16] Baylor Coll Med, Texas Childrens Hosp, Dept Pediat, Div Nephrol, Houston, TX USA
基金
美国国家卫生研究院;
关键词
area under the concentration-time curve to minimum inhibitory concentration ratio; critically ill pediatric patients; pediatric intensive care unit; pharmacokinetics; vancomycin; INFECTIOUS-DISEASES SOCIETY; UNDER-THE-CURVE; STAPHYLOCOCCUS-AUREUS INFECTIONS; HEALTH-SYSTEM PHARMACISTS; AMERICAN SOCIETY; CHILDREN; PHARMACOKINETICS; GUIDELINES; OUTCOMES; ADULTS;
D O I
10.1097/CCE.0000000000001159
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
OBJECTIVES:To investigate which independent factor(s) have an impact on the pharmacokinetics of vancomycin in critically ill children, develop an equation to predict the 24-hour area under the concentration-time curve from a trough concentration, and evaluate dosing regimens likely to achieve a 24-hour area under the concentration-time curve to minimum inhibitory concentration ratio (AUC24/MIC) greater than or equal to 400.DESIGN:Prospective population pharmacokinetic study of vancomycin.SETTING:Critically ill patients in quaternary care PICUs.PATIENTS:Children 90 days old or older to younger than 18 years who received IV vancomycin treatment, irrespective of the indication for use, in the ICUs at the University of Maryland Children's Hospital and Texas Children's Hospital were enrolled.INTERVENTIONS:Vancomycin was prescribed at doses and intervals chosen by the treating clinicians.MEASUREMENTS AND MAIN RESULTS:A median of four serum levels of vancomycin per patient were collected along with other variables for up to 7 days following the first administration. These data were used to characterize vancomycin pharmacokinetics and evaluate the factors affecting the variability in achieving AUC24/MIC ratio greater than or equal to 400 in PICU patients who are not on extracorporeal therapy. A total of 302 children with a median age of 6.0 years were enrolled. A two-compartment model described the pharmacokinetics of vancomycin with the clearance of 2.76 L/hr for a typical patient weighing 20 kg. The glomerular filtration rate estimated using either the bedside Schwartz equation or the chronic kidney disease in children equation was the only statistically significant predictor of clearance among the variables evaluated, exhibiting equal predictive performance. The trough levels achieving AUC24/MIC = 400 were 5.6-10.0 mu g/mL when MIC = 1 mu g/mL. The target of AUC24/MIC greater than or equal to 400 was achieved in 60.4% and 36.5% with the typical dosing regimens of 15 mg/kg every 6 and 8 hours (q6h and q8h), respectively.CONCLUSIONS:The pharmacokinetics of vancomycin in critically ill children were dependent on the estimated glomerular filtration rate only. Trough concentrations accurately predict AUC24. Typical pediatric vancomycin dosing regimens of 15 mg/kg q6h and q8h will often lead to AUC24/MIC under 400.
引用
收藏
页数:11
相关论文
共 40 条
  • [1] [Anonymous], 2012, KIDNEY DIS IMPROVING
  • [2] Bonazza Sarah, 2016, J Pediatr Pharmacol Ther, V21, P486, DOI 10.5863/1551-6776-21.6.486
  • [3] Pharmacokinetic changes in critical illness
    Boucher, Bradley A.
    Wood, G. Christopher
    Swanson, Joseph M.
    [J]. CRITICAL CARE CLINICS, 2006, 22 (02) : 255 - +
  • [4] Chhim RF, 2013, J PEDIAT INF DIS SOC, V2, P259, DOI 10.1093/jpids/pis083
  • [5] Pharmacokinetics of Vancomycin in Pediatric Patients Receiving Intermittent Hemodialysis or Hemodiafiltration
    Chung, Erin
    Tjon, James A.
    Nemec, Rosaleen M.
    Nalli, Nadya
    Harvey, Elizabeth A.
    Licht, Christoph
    Seto, Winnie
    [J]. KIDNEY INTERNATIONAL REPORTS, 2021, 6 (04): : 1003 - 1014
  • [6] Optimizing Vancomycin Therapy in Critically Ill Children: A Population Pharmacokinetics Study to Inform Vancomycin Area under the Curve Estimation Using Novel Biomarkers
    Downes, Kevin J.
    Zuppa, Athena F.
    Sharova, Anna
    Neely, Michael N.
    [J]. PHARMACEUTICS, 2023, 15 (05)
  • [7] Pathophysiology, evaluation, and Management of edema in Childhood Nephrotic Syndrome
    Ellis, Demetrius
    [J]. FRONTIERS IN PEDIATRICS, 2016, 3
  • [8] Fernandez Eva, 2011, Pharmaceutics, V3, P53, DOI 10.3390/pharmaceutics3010053
  • [9] Desired Vancomycin Trough Serum Concentration for Treating Invasive Methicillin-resistant Staphylococcal Infections
    Frymoyer, Adam
    Guglielmo, B. Joseph
    Hersh, Adam L.
    [J]. PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2013, 32 (10) : 1077 - 1079
  • [10] The Effect of Critical Illness on Drug Distribution
    Gonzalez, Daniel
    Conrado, Daniela J.
    Theuretzbacher, Ursula
    Derendorf, Hartmut
    [J]. CURRENT PHARMACEUTICAL BIOTECHNOLOGY, 2011, 12 (12) : 2030 - 2036